Will design, lead and execute the Company's commercialization efforts to market it's flagship product ALM-488. This will enable the transformation from development to a commercial stage company.

I optimized the commercialization strategy and analysis for companies with assets in pre-launch or late-stage of product lifecycle. In this role, I prepared recommendations for the due diligence group toensure profitability. I supported clients in developing tactical plans to streamline prelaunch activities forthe first commercial asset to accelerate revenue.➥ I overhauled performance of 3 companies in distress by strategizing field deployments, redefiningcustomer targets, optimizing resources, and fine-tuning product strategy. As a result, I gainedinvestment bank funding for ongoing operations.➥ My team and I revitalized and mapped out customer messaging, improving engagement and revenue.➥ I assisted a small radio-pharma company in the development of go-to-market strategy andcoordinated pre-launch activities.➥ I worked with Chief Commercial Officer on strategic and tactical launch plan, while also creating budgets and revenue forecast.

I operationalized a digital therapeutics/telehealth company from Israel into the US, setting up thestructure from the ground up and overseeing administrative, commercial and legal aspects, includingpricing, targeting, and customer engagement. I positioned the company to bring its flagshipproduct Moovcare to market with a sound regulatory and legal foundation.➥ I put in place the corporate plan to meet the US goals, including operating during Covid-19.➥ I mapped out funding, strategic imperatives, tactical reimbursement, and coverage by the US healthsystem.➥ I also led market access, business development, sales, marketing, and regulatory activities.

Successfully served as Interim CEO & President to lead a corporate reorganization triggered by the company's investors and Board of Directors as a result of the company's loss of CE Mark of Pulsante SPG Microstimulator System for Cluster Headache. Led the organization through the 510K De Novo application to the US FDA and ISO13485(2016) certification..

I led a publicly traded, commercial stage company with 50 employees and a recently launchedradiopharmaceutical product. In close partnership with nuclear medicine technologists, doctors, andscientists, I established clear lines of communication with the shareholders, to achieve consensus andcommon language setting a new path for commercialization.➥ I transformed the company from a diagnostics company to an immunodiagnostics andimmunotherapeutic company. Here, I put in place a new C-level structure and a new commercial team,revitalized partnerships, and doubled growth YoY.➥ I brought spending under control, instituting accountability metrics and expectations for eachdepartment head, requiring justifications for any variation.➥ I created a significant culture shift which included C-suite meetings for consensus and a cooperativeteam culture. I also held monthly company-wide calls to report on progress and define next steps.➥ I designed a commercial organization to accelerate revenues of the US & EU approved flagshipimmunodiagnostic, Lymphoseek, resulting in a 2.5x year over year growth.

I orchestrated the globalization of a US-based company into international markets whilecommercializing a key asset. In this role, I steered a global, cross-functional team of 25 people with a footprint in 40+ countries. I led all global operational and commercialization efforts in Europe, Asia,Middle East, and Latin America.➥ I propelled revenues from $7.7M in 2008 to ~$300M in 2012 by launching and managing a multidisciplinary commercial team and infrastructure.➥ I strategized pricing, distribution, and government affairs for the product for colorectal cancertreatment; received approvals from Medicare and Medicare.➥ I globalized operations in major markets (Europe, Japan, Middle East, and Latin America) throughinnovative models and partnerships in less than 1 year.➥ I designed and launched European operational infrastructure and established a fully operationalaffiliate in Japan.

Responsible for leading all global commercialization efforts in Europe, Asia, Middle East and Latin America with focus on P&L, operations and expansion strategies.

Responsible for oversight of all functional areas within the commercial team including sales, operations, brand management, reimbursement, account management and business solutions. Promoted to SVP, Deputy Chief Commercial Officer.

Responsible for leading national strategic and tactical teams for marketed and products in development in the following areas:Account managment (National and Regional), Marketing & Brand Management, Distribution, Pricing & Contracting, Reimbursement, Government Affairs & Policy.

Responsible for managing all aspects of contracting and key accounts at the regional level.